Responses
Regular and young investigator award abstracts
Novel single-agent immunotherapies
700 EphA2/CD137 Bicycle tumor-targeted immune cell agonists (TICAsTM) induce tumor regressions, immunogenic memory, and reprogramming of the tumor immune microenvironment
Compose a Response to This Article
Other responses
No responses have been published for this article.
